FMC’s India Divestiture: A Cash Infusion, Not a Cure

What happened

FMC announced the sale of its India commercial business, a move consistent with its previously disclosed divestiture plan. The sale will provide cash to pay down debt, but the company remains under pressure from weak operating cash flow and tight covenants. The master report highlighted that FMC’s equity is a levered bet on cash conversion, not end-market recovery. This transaction reduces near-term liquidity risk but does not address the structural challenges of pricing pressure and extended payment terms in Latin America. Until operating cash flow turns positive without increased factoring, the equity remains a speculative recovery play.

Implication

Investors should not view this as a turning point. FMC still needs to demonstrate sustainable free cash flow and debt reduction. The India sale proceeds are a one-time boost; the real test is whether Latin America collections normalize in 2026. Until then, the stock is a high-risk, low-visibility situation. Attractive entry remains at $14 or below, with a re-assessment window of 3-6 months to see if cash flow inflects.

Thesis delta

The India divestiture was already baked into the base case. The news does not alter the thesis that FMC’s equity depends on cash conversion, not asset sales. If anything, the sale underscores management’s need to monetize assets to stay within covenants, confirming the bear scenario risks. No change to the WAIT rating.